You are here

Our science / Clinical Trials / Find a Trial / NCT00483002

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets

Back to Search Print Save as PDF Bookmark Trial

NCT00483002

Last updated on May 10, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Smoking Cessation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects selected for this study are those who would have been prescribed Champix
tablets by the physician according to the subject's condition in usual clinical
practice.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
NCT00483002
Pfizer
Completed
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Smoking Cessation
A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline
NCT00143299
All Genders
18+
Years
Multiple Sites
Smoking Cessation
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation
NCT00141167
All Genders
18+
Years
Multiple Sites
Smoking Cessation
A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation
NCT00150241
All Genders
18+
Years
Multiple Sites
Smoking Cessation
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
NCT00143364
All Genders
18+
Years
Multiple Sites
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets
To monitor use in real practice including safety and efficacy of Champix tablets 0.5mg, 1mg medication for 12 weeks in smokers
No sampling method will be applied to this study.
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Healthy smokers
Smoking Cessation
Drug: varenicline
As prescribed by physician in usual clinical practice.
Other Name: Champix, Chantix, CP-526,555
Healthy smokers
Intervention: Drug: varenicline
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
3719
May 2011
May 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects selected for this study are those who would have been prescribed Champix tablets by the physician according to the subject's condition in usual clinical practice.

Exclusion Criteria:
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00483002
A3051083
Yes
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2012

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now